| Jose Rafael Uriarte, ATC | |
|
311 E Spruce St, Garden City, KS 67846-5614 | |
| (620) 275-3006 | |
| Not Available |
| Full Name | Jose Rafael Uriarte |
|---|---|
| Gender | Male |
| Speciality | Preventive Medicine - Sports Medicine |
| Location | 311 E Spruce St, Garden City, Kansas |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1942728167 | NPI | - | NPPES |
| AT.0001864 | Other | CO | ATHLETIC TRAINING LICENSE |
| 24-01217 | Other | KS | ATHLETIC TRAINING LICENSE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2083S0010X | Preventive Medicine - Sports Medicine | 24-01217 (Kansas) | Secondary |
| 2083S0010X | Preventive Medicine - Sports Medicine | AT.0001864 (Colorado) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Jose Rafael Uriarte, ATC 718 Berkeley Ave, Alamosa, CO 81101-2002 Ph: (719) 298-2252 | Jose Rafael Uriarte, ATC 311 E Spruce St, Garden City, KS 67846-5614 Ph: (620) 275-3006 |
News Archive
Tinnitus, or ringing in the ears, does not appear to be a highly inherited condition (i.e., does not pass frequently from parents to offspring), according to a report in the February issue of Archives of Otolaryngology-Head & Neck Surgery, one of the JAMA/Archives journals.
Home-delivered meals bring not only food to seniors but also the opportunity to remain in their homes. A new study by Brown University public health researchers projects that if every U.S. state in the lower 48 expanded the number of seniors receiving meals by just 1 percent, 1,722 more Medicaid recipients avoid living in a nursing home and most states would experience a net annual savings from implementing the expansion.
The type of dietary fats consumed by middle-aged men, especially polyunsaturated fats and linoleic acids, may be more important than total fat intake in reducing the risk of cardiovascular deaths, according to a study in the January 24 issue of Archives of Internal Medicine.
Promedior, Inc., a clinical stage biotechnology company developing novel biologic therapeutics for the treatment of fibrosis, announced today that it has initiated a Phase 2 clinical trial to evaluate PRM-151, its lead product candidate, in patients with myelofibrosis.
While heart attack rates across all income levels have declined significantly over the last 15 years, people living in low-income communities are still more likely to be hospitalized for acute myocardial infarction (AMI), according to a new study published by Yale School of Medicine researchers in the journal JAMA Cardiology.
› Verified 1 days ago